GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
- Conditions
- Influenza
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 110
- Registration Number
- NCT00505453
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT00504790
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00504816
- Locations
- 🇺🇸
GSK Investigational Site, Miramar, Florida, United States
A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00504439
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study Of RV-39 In Patients Who Also Have Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00503009
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 680
- Registration Number
- NCT00502775
- Locations
- 🇺🇸
GSK Investigational Site, West Allis, Wisconsin, United States
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
- Conditions
- Influenza
- Interventions
- Biological: Fluarix™Biological: Pandemic Influenza Vaccine (GSK1562902A)
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 138
- Registration Number
- NCT00502593
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
VZV PCR Sampling Validation Study
- Conditions
- Herpes Zoster
- Interventions
- Procedure: Herpes zoster sampling procedure for VZV PCRProcedure: Blood sampling
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00501670
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers
- Conditions
- Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00501397
- Locations
- 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00501930
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States